Sagent Pharmaceuticals, Inc. (SGNT2)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Allan Oberman
Employees:
440
1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG, IL 60195
847-908-1604

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Sagent Pharmaceuticals, Inc. develops, sources, manufactures, and markets injectable pharmaceuticals in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and s...

Data derived from most recent annual or quarterly report
Market Cap 0 Shares Outstanding0 Avg 30-day Volume 443.243 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.17
Price to Revenue1.6526 Debt to Equity0.0236 EBITDA-42.393 Million
Price to Book Value1.939 Operating Margin-17.866 Enterprise Value454.623 Million
Current Ratio2.156 EPS Growth-1.951 Quick Ratio1.032
1 Yr BETA 0.9974 52-week High/Low 0.0 / Profit Margin-8.4732
Operating Cash Flow Growth-2422.6351 Altman Z-Score3.0617 Free Cash Flow to Firm -49.133 Million
View SEC Filings from SGNT2 instead.

View recent insider trading info

Funds Holding SGNT2 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SGNT2 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FLANAGAN ROBERT J

  • Director
No longer subject to file 2016-08-29 0

BEHRENS MARY TAYLOR

  • Director
No longer subject to file 2016-08-29 0

HARMON J FRANK EVP, GLOBAL OPERATIONS

  • Officer
No longer subject to file 2016-08-29 0

SINGER JONATHON M EVP AND CFO

  • Officer
No longer subject to file 2016-08-29 0

VIVO VENTURES V, LLC

VIVO VENTURES FUND V, L.P.

VIVO VENTURES V AFFILIATES FUND, L.P.

  • 10% Owner
0 2016-08-29 0

KRIZMAN ANTHONY

  • Director
No longer subject to file 2016-08-29 0

GREVE JEFFREY W. VICE PRESIDENT, CONTROLLER

  • Officer
No longer subject to file 2016-08-29 0

YANAI SHLOMO

  • Director
No longer subject to file 2016-08-29 0

FEKETE MICHAEL

  • Director
No longer subject to file 2016-08-29 0

OBERMAN ALLAN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
No longer subject to file 2016-08-29 0

WARD MICHAEL V. CHIEF LEGAL OFF. AND SECRETARY

  • Officer
No longer subject to file 2016-08-29 0

BRYNJELSEN SEAN EVP, BUSINESS DEVELOPMENT

  • Officer
No longer subject to file 2016-08-29 0

BULLOCK DONALD R EXECUTIVE V.P. SALES

  • Officer
No longer subject to file 2016-08-29 0

VIVO VENTURES VI, LLC

VIVO VENTURES FUND VI, L.P.

VIVO VENTURES VI AFFIILATES FUND, L.P.

  • 10% Owner
3,481,652 2016-04-21 0

PATTERSON ALBERT EVP, NAT. ACCTS AND CORP. DEV.

48,690 2016-03-19 0

DRAKE LORIN EXECUTIVE VP, SALES

39,172 2016-02-25 0

LOGERFO MICHAEL PRESIDENT, CLO

54,292 2016-02-25 0

SHEA THOMAS JOSEPH VP, GLOBAL ALLIANCE MANAGEMENT

10,442 2016-02-22 0

KUNG FRANK

  • Director
0 2015-04-09 0

YORDON JEFFREY

  • Director
686,014 2015-02-27 0

HUSSEY JAMES M PRESIDENT

  • Officer
11,058 2015-02-25 0

MORGAN STANLEY INVESTMENT MANAGEMENT INC

MORGAN STANLEY AIP GP LP

  • 10% Owner
No longer subject to file 2015-01-26 0

YU CHEN-MING INTERIM COO

  • Officer
0 2012-09-07 0

PAULI RONALD CHIEF FINANCIAL OFFICER

  • Officer
3,680 2012-02-22 0

SPERANS JAMES

  • Director
0 2012-02-22 0

HEBEDA DAVE VICE PRESIDENT, FINANCE

  • Officer
0 2012-02-22 0

CHINA RENAISSANCE CAPITAL INVESTMENT II GP

CHINA HARVEST FUND II, LP

CHINA RENAISSANCE CAPITAL INVESTMENT II, L.P.

KEY GATE INVESTMENTS LTD

  • 10% Owner
2,779,003 2012-02-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments